Clinical trials: Depressed
Depressive Disorder, Major
Coil Positioning in Navigated Transcranial Magnetic Stimulation Feasibility in Depression Patients Trial
The objective of this study is to evaluate the feasibility of adding a navigational system to traditional repetitive Transcranial Magnetic Stimulation (rTMS, referred to in this application as nTMS) as a way to establish and…
- Trial name
- CONFIDENT (NCT03795051)
- Testing
- Navigated Transcranial Magnetic Stimulation
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Magstim
Major Depressive Disorder
AZD6765 Severe Major Depressive Disorder (MDD) IV
The purpose of this research study is to determine whether AZD6765 has an effect on the patient's depression when taken together with current depression medication.
- Trial name
- NCT00781742
- Testing
- AZD6765
- Where
- 27 sites in United States
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Depression, Depression Moderate
Kintsugi Voice Device Pilot Study
A prospective, single arm, non-randomized, pilot clinical validation study to evaluate the ability of the Kintsugi Voice Device (the Device) to aid clinical assessment for depression by comparing its output with a diagnosis made…
- Conditions
- Depression, Depression Moderate, Depression Severe, Depression Mild
- Trial name
- NCT06374056
- Testing
- Kintsugi Voice Device
- Where
- United States
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Major Depressive Disorder
Brainsway DTMS for Treatment of MDD Using iTBS
The safety and effectiveness of the BrainsWay deep transcranial magnetic stimulation (DTMS) device for the intended use of Major Depressive Disorder (MDD) using the intermittent theta-burst (iTBS) stimulation protocol will be…
- Trial name
- NCT04679753
- Testing
- Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS), Brainsway DTMS with High Frequency (HF) Stimulation
- Where
- Canada
- Volunteers
- 177 people
- Sponsor
- Brainsway
Depression
Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)
This study is designed to characterize the regional distribution of [11C] ABP688 in brain by positron emission tomography (PET).
- Trial name
- NCT01528241
- Testing
- ABP688
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Depressive Disorder, Depression
A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression
A clinical study to evaluate safety, tolerability and efficacy of oral administration of ganaxolone in women with postpartum depression
- Conditions
- Depressive Disorder, Depression, Depression, Postpartum, Behavioral Symptoms
- Trial name
- NCT03460756
- Testing
- Ganaxolone
- Where
- 33 sites in United States
- Volunteers
- 84 people
- Sponsor
- Marinus Pharmaceuticals
Psychotic Depression, Severe Major Depression With Psychotic Features
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of mifepristone followed by antidepressant versus placebo followed by…
- Conditions
- Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
- Trial name
- NCT00637494
- Testing
- mifepristone
- Where
- 42 sites in United States
- Volunteers
- 292 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression
The study will evaluate the safety and efficacy of AV-101.
- Trial name
- ELEVATE (NCT03078322)
- Testing
- AV-101
- Where
- 22 sites in United States
- Volunteers
- 180 people
- Sponsor
- VistaGen Therapeutics, Inc.
Depression / Major Depressive Disorder, Anxiety
Activating Voice Journaling for Mental Health With Voice Biomarkers
This retrospective observational study evaluated the relationship between voice characteristics and self-reported mental health symptoms using longitudinal data collected through the Kintsugi Voice Journaling app.
- Trial name
- NCT07789808
- Where
- United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Major Depressive Disorder Co-Occurrent With Anxiety, Adult Patients
First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic
According to the local guidelines (Recommendation for General Practitioners), the first choice Anti-Depressant (AD) in Major Depressive Disorder (MDD) in primary care should be selective serotonin reuptake inhibitors (SSRI), e.g.
- Conditions
- Major Depressive Disorder Co-Occurrent With Anxiety, Adult Patients, Newly Diagnosed Depression
- Trial name
- FIAT (NCT05291897)
- Where
- 6 sites in Czechia
- Volunteers
- 28 people
- Sponsor
- Angelini Pharma Česká republika s.r.o.
Depression, Postpartum
Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine
Type 2 Diabetes (T2DM) is a life-long, chronic condition affecting an individuals' ability to regulate glucose levels in the blood. Diabetes can cause many severe complications if not treated properly.
- Trial name
- NCT01602913
- Testing
- Pravastatin alone, Paroxetine alone, Pravastatin and paroxetine combined
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients
The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression.
- Trial name
- NCT03833206
- Testing
- PDC-1421 Capsule
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- BioLite, Inc.
Depressive Disorder, Major
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with major depressive disorder (MDD).
- Trial name
- NCT03614156
- Testing
- Rapastinel
- Where
- 52 sites in United States, Hungary and 3 more
- Volunteers
- 363 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Postpartum Depressive Disorder
Quetiapine in Postpartum Depression
The purpose of the study is to evaluate the efficacy and tolerability of quetiapine in female patients with postpartum depressive disorder with psychotic symptoms
- Trial name
- NCT00681668
- Testing
- Quetiapine
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- AstraZeneca
Depression, Suicide
Antidepressant Drug Exposure and Risk of Suicide Attempt Resulting in Medical Intervention in US Adults
The primary objective of the study is to estimate the incidence of suicide attempts resulting in a medical encounter or hospitalization in seven propensity matched cohorts of subjects: patients treated with duloxetine for…
- Trial name
- NCT00763724
- Volunteers
- 254,432 people
- Sponsor
- Eli Lilly and Company
Treatment-Resistant Depression
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
The main purpose of this study was to evaluate safety and efficacy of a single injection of MIJ821 in addition to standard of care (SoC) pharmacological anti-depressant treatment in participants with treatment-resistant…
- Trial name
- NCT05454410
- Testing
- MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg
- Where
- 16 sites in United States, Japan and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
This study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Major Depressive Disorder.
- Trial name
- NEST-MDD (NCT01370733)
- Testing
- NEST-1 (NeoSync EEG Synchronized TMS)
- Where
- 18 sites in United States
- Volunteers
- 202 people
- Sponsor
- Wave Neuroscience
Depression - Major Depressive Disorder, Anxiety
Validation of Accexible Screening and Self-Administered Activities for Emotional Well-Being in a University Hospital (UaDEC)
Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD).
- Trial name
- NCT07578155
- Testing
- AcceXible
- Where
- Mexico
- Volunteers
- 902 people, healthy volunteers welcome
- Sponsor
- Accexible
Post-Concussion Symptoms, Insomnia
Neurotechnology Following Traumatic Brain Injury
This two-part study seeks to improve symptoms such as pain and sleep problems after concussion, or mild traumatic brain injury (mTBI).
- Conditions
- Post-Concussion Symptoms, Insomnia, Pain, Chronic, Depressive Symptoms
- Trial name
- Cereset (NCT03649958)
- Testing
- HIRREM-SOP or Cereset, Cereset 2x
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Brain State Technologies, LLC
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like a medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01197508
- Testing
- TC-5214
- Where
- 87 sites in Argentina, Brazil and 15 more
- Volunteers
- 696 people
- Sponsor
- AstraZeneca